THOMAS CROWLEY: Open Payments
NPI 1558148593 · SULLIVAN, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$296 in 14 payments from 10 companies in 2025. Trend: 2023 $366 · 2024 $867 · 2025 $296
Food & beverage: $296
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 3 | $53 |
| Axsome Therapeutics, Inc. | 2 | $51 |
| Teva Pharmaceuticals USA, Inc. | 2 | $46 |
| Neuronetics, Inc. | 1 | $25 |
| Noven Therapeutics, LLC | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $21 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
| PFIZER INC. | 1 | $19 |
| Janssen Pharmaceuticals, Inc | 1 | $17 |
Products named: Auvelity, UZEDY, NEUROSTAR TMS THERAPY SYSTEM, Xelstrym, ABILIFY MAINTENA, CAPLYTA, FANAPT, AUSTEDO XR.
Industry payments across IN — which companies pay providers there.
